Common Stock, $0.001 par value
- Symbol
- SPRO
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.02 · 8-K
Spero Therapeutics, Inc.
SPRONASDAQEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On October 26, 2026, Spero Therapeutics, Inc. (the “Company”) announced that Timothy Keutzer, the Company’s Chief Operating Officer, will retire from the Company effective as of December 31, 2026 (the “Effective Date”).…
Company context
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company’s lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immunological & inflammatory diseases. For more information, visit www.sperotx.com.
Current securities
Registered securities in this filing
SPERO THERAPEUTICS, INC. · 8-K · Filed 2026-10-27
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On October 26, 2026, Spero Therapeutics, Inc. (the “Company”) announced that Timothy Keutzer, the Company’s Chief Operating Officer, will retire from the Company effective as of December 31, 2026 (the “Effective Date”). In connection with his retirement, the Company expects to enter into a consulting arrangement with Mr. Keutzer on or about the Effective Date, pursuant to which Mr. Keutzer will provide advisory services to the Company in support of the transition until approximately February 28, 2027, unless earlier terminated by either party on fifteen days’ prior written notice (the “Consulting Period”). Pursuant to the terms of the Consulting Agreement, Mr. Keutzer will be paid an hourly rate for his services during the Consulting Period. Mr. Keutzer’s retirement follows 11 years of dedicated service, leadership and significant contributions to the Company.